Announcements
Investor News
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
Første 6 måneder af 2024: Fortsat stærk vækst i salget af NGAL-tests i USA og fokuseret eksekvering af alle elementer i BioPortos strategi
Thu, 15 Aug 2024 06:58 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024
Thu, 15 Aug 2024 06:37 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting
Wed, 07 Aug 2024 11:04 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms
Tue, 30 Jul 2024 15:15 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
Mon, 29 Jul 2024 14:35 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
Fri, 26 Jul 2024 15:15 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker
Wed, 17 Jul 2024 15:50 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury
Thu, 11 Jul 2024 15:15 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto confirms market acceptance of NGAL products with US standing order.
Mon, 01 Jul 2024 15:30 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
Tue, 18 Jun 2024 06:14 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
Mon, 17 Jun 2024 17:04 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
First Quarter 2024: Strong growth in US sales of The NGAL Test
Wed, 08 May 2024 06:21 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
BioPorto A/S
BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting
Thu, 02 May 2024 11:53 GMT
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)
![BioPorto](https://bioporto.com/wp-content/uploads/2019/11/BioPorto_Logo-300x56.png)